Diabetes and percutaneous coronary revascularization in the drug-eluting stent era

David M. Safley, Steven P. Marso

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Diabetes mellitus has reached epidemic proportions and is associated with decreased event-free survival following coronary revascularization. Although the historical complication rates for diabetic patients following percutaneous coronary intervention have been less than acceptable, the emerging drug-eluting stent technology when coupled with an aggressive adjunctive pharmacological regimen will improve the complication rates following percutaneous revascularization for this high-risk group of patients. This review will focus on the historical data associated with revascularization, percutaneous and surgical, and diabetes mellitus and will highlight the emerging data of drug-eluting stents and adjunctive pharmacology.

Original languageEnglish (US)
Pages (from-to)542-550
Number of pages9
JournalHerz
Volume29
Issue number5
DOIs
StatePublished - Aug 2004

Fingerprint

Drug-Eluting Stents
Percutaneous Coronary Intervention
Diabetes Mellitus
Pharmacology
Diabetes Complications
Disease-Free Survival
Technology

Keywords

  • Coronary artery disease
  • Diabetes mellitus
  • Drug eluting stents
  • Percutaneous coronary revascularization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Diabetes and percutaneous coronary revascularization in the drug-eluting stent era. / Safley, David M.; Marso, Steven P.

In: Herz, Vol. 29, No. 5, 08.2004, p. 542-550.

Research output: Contribution to journalArticle

@article{c4c29caa66e34329aba9e7460e7062a3,
title = "Diabetes and percutaneous coronary revascularization in the drug-eluting stent era",
abstract = "Diabetes mellitus has reached epidemic proportions and is associated with decreased event-free survival following coronary revascularization. Although the historical complication rates for diabetic patients following percutaneous coronary intervention have been less than acceptable, the emerging drug-eluting stent technology when coupled with an aggressive adjunctive pharmacological regimen will improve the complication rates following percutaneous revascularization for this high-risk group of patients. This review will focus on the historical data associated with revascularization, percutaneous and surgical, and diabetes mellitus and will highlight the emerging data of drug-eluting stents and adjunctive pharmacology.",
keywords = "Coronary artery disease, Diabetes mellitus, Drug eluting stents, Percutaneous coronary revascularization",
author = "Safley, {David M.} and Marso, {Steven P.}",
year = "2004",
month = "8",
doi = "10.1007/s00059-004-2615-z",
language = "English (US)",
volume = "29",
pages = "542--550",
journal = "Herz",
issn = "0340-9937",
publisher = "Urban und Vogel",
number = "5",

}

TY - JOUR

T1 - Diabetes and percutaneous coronary revascularization in the drug-eluting stent era

AU - Safley, David M.

AU - Marso, Steven P.

PY - 2004/8

Y1 - 2004/8

N2 - Diabetes mellitus has reached epidemic proportions and is associated with decreased event-free survival following coronary revascularization. Although the historical complication rates for diabetic patients following percutaneous coronary intervention have been less than acceptable, the emerging drug-eluting stent technology when coupled with an aggressive adjunctive pharmacological regimen will improve the complication rates following percutaneous revascularization for this high-risk group of patients. This review will focus on the historical data associated with revascularization, percutaneous and surgical, and diabetes mellitus and will highlight the emerging data of drug-eluting stents and adjunctive pharmacology.

AB - Diabetes mellitus has reached epidemic proportions and is associated with decreased event-free survival following coronary revascularization. Although the historical complication rates for diabetic patients following percutaneous coronary intervention have been less than acceptable, the emerging drug-eluting stent technology when coupled with an aggressive adjunctive pharmacological regimen will improve the complication rates following percutaneous revascularization for this high-risk group of patients. This review will focus on the historical data associated with revascularization, percutaneous and surgical, and diabetes mellitus and will highlight the emerging data of drug-eluting stents and adjunctive pharmacology.

KW - Coronary artery disease

KW - Diabetes mellitus

KW - Drug eluting stents

KW - Percutaneous coronary revascularization

UR - http://www.scopus.com/inward/record.url?scp=4444246286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444246286&partnerID=8YFLogxK

U2 - 10.1007/s00059-004-2615-z

DO - 10.1007/s00059-004-2615-z

M3 - Article

VL - 29

SP - 542

EP - 550

JO - Herz

JF - Herz

SN - 0340-9937

IS - 5

ER -